Stay updated on CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial

Sign up to get notified when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The record now describes a completed Phase 1–2 study of APX005M (sotigalimab) combined with nivolumab for non-small cell lung cancer and metastatic melanoma. It includes eligibility criteria, study design and outcomes, locations, results-related dates, and study documents.
    Difference
    76%
    Check dated 2026-11-09T14:00:50.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T16:15:06.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    A banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T14:45:54.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov page displaying a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-19T14:32:29.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-12T14:36:12.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study details with an error screen.
    Difference
    20%
    Check dated 2026-09-21T19:56:28.000Z thumbnail image

Stay in the know with updates to CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.